MedTrace Logo

Safety and Immunogenicity Study of SeV-G(NP) HIV Vaccine Administered Intranasally and Ad35-GRIN HIV Vaccine Given Intramuscularly in Prime-Boost Regimens in HIV-Uninfected Volunteers

NCT01705990 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2015-08-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and immunogenicity of Sendai HIV vaccine SeV-G(NP) given intranasally and Ad35-GRIN administered intramuscularly in prime-boost regimens in HIV-uninfected, healthy adult volunteers.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

SeV-G(NP) (0.2mL, 2x10^7 CIU)

Delivered intranasally by drops

BIOLOGICAL

SeV-G(NP) (0.2mL, 2x10^8 CIU)

Delivered intranasally by drops

BIOLOGICAL

Ad35-GRIN (0.5mL)

(1x10\^10 vp) Delivered intramuscularly by standard syringe and needle injection

Sponsors & Collaborators

  • International AIDS Vaccine Initiative

    lead NETWORK

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2015-03-31

Countries

  • Kenya
  • Rwanda
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01705990 on ClinicalTrials.gov